TMCnet News
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development SummitALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021: Needham Virtual Healthcare Conference
Wet AMD & DME Drug Development Summit
About Clearside Biomedical Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com. Investor and Media Contacts: Jenny Kobin Source: Clearside Biomedical, Inc. |